Citations (51)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Kin-Lun Tsang & Shu-Leong Ho. (2001) Estrogen therapy in postmenopausal women with Parkinson’s disease. Expert Review of Neurotherapeutics 1:2, pages 135-137.
Read now
Read now
Reuven Sandyk. (1990) Pineal Melatonin Functions: Possible Relevance to Parkinson's Disease. International Journal of Neuroscience 50:1-2, pages 37-54.
Read now
Read now
Articles from other publishers (49)
Bruno Dutra Arbo, Lucia Emanueli Schimith, Michele Goulart dos Santos & Mariana Appel Hort. (2022) Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation. European Journal of Pharmacology 919, pages 174800.
Crossref
Crossref
Indu Subramanian, Soania Mathur, Annelien Oosterbaan, Richelle Flanagan, Adrienne M. Keener & Elena Moro. (2022) Unmet Needs of Women Living with Parkinson's Disease: Gaps and Controversies. Movement Disorders 37:3, pages 444-455.
Crossref
Crossref
Hannah J. Roeder & Enrique C. Leira. (2021) Effects of the Menstrual Cycle on Neurological Disorders. Current Neurology and Neuroscience Reports 21:7.
Crossref
Crossref
Santosh Kumar Singh & Rajesh Singh. 2021. Obesity and Cancer. Obesity and Cancer
301
338
.
Christina Tremblay, Nooshin Abbasi, Yashar Zeighami, Yvonne Yau, Mahsa Dadar, Shady Rahayel & Alain Dagher. (2020) Sex effects on brain structure in de novo Parkinson’s disease: a multimodal neuroimaging study. Brain 143:10, pages 3052-3066.
Crossref
Crossref
Jung Eun Yoo, Dong Wook Shin, Wooyoung Jang, Kyungdo Han, Dahye Kim, Hye-Sung Won & Hye Soon Park. (2020) Female reproductive factors and the risk of Parkinson’s disease: a nationwide cohort study. European Journal of Epidemiology 35:9, pages 871-878.
Crossref
Crossref
Daniel Zielonka & Barbara Stawinska-Witoszynska. (2020) Gender Differences in Non-sex Linked Disorders: Insights From Huntington's Disease. Frontiers in Neurology 11.
Crossref
Crossref
Sara Meoni, Antonella Macerollo & Elena Moro. (2020) Sex differences in movement disorders. Nature Reviews Neurology 16:2, pages 84-96.
Crossref
Crossref
Daniel M. Mason, Yaqin Wang, Tarun N. Bhatia, Kristin M. Miner, Sara A. Trbojevic, John F. Stolz, Kelvin C. Luk & Rehana K. Leak. (2019) The center of olfactory bulb‐seeded α‐synucleinopathy is the limbic system and the ensuing pathology is higher in male than in female mice. Brain Pathology 29:6, pages 741-770.
Crossref
Crossref
Mélanie Bourque, Marc Morissette & Thérèse Di Paolo. (2019) Repurposing sex steroids and related drugs as potential treatment for Parkinson's disease. Neuropharmacology 147, pages 37-54.
Crossref
Crossref
Michael T. Hayes. 2019. Neurology and Psychiatry of Women. Neurology and Psychiatry of Women
213
217
.
Mavis A. Tenkorang, Brina Snyder & Rebecca L. Cunningham. (2018) Sex-related differences in oxidative stress and neurodegeneration. Steroids 133, pages 21-27.
Crossref
Crossref
Santosh K. Yadav, Nagarajan Kathiresan, Suyash Mohan, Georgia Vasileiou, Anup Singh, Deepak Kaura, Elias R. Melhem, Rakesh K. Gupta, Ena Wang, Francesco M. Marincola, Arijitt Borthakur & Mohammad Haris. (2016) Gender-based analysis of cortical thickness and structural connectivity in Parkinson’s disease. Journal of Neurology 263:11, pages 2308-2318.
Crossref
Crossref
Sathiji Nageshwaran, Marsha Smith & Yvette M. Bordelon. 2016. Neurological illness in pregnancy. Neurological illness in pregnancy
179
190
.
Glenda E. Gillies, Ilse S. Pienaar, Shiv Vohra & Zahi Qamhawi. (2014) Sex differences in Parkinson’s disease. Frontiers in Neuroendocrinology 35:3, pages 370-384.
Crossref
Crossref
Daniel P. Czech, Joohyung Lee, Jeanne Correia, Hannah Loke, Eva K. Möller & Vincent R. Harley. (2014) Transient Neuroprotection by SRY Upregulation in Dopamine Cells Following Injury in Males. Endocrinology 155:7, pages 2602-2612.
Crossref
Crossref
Fabienne S. Sprenger, Klaus Seppi, Elisabeth Wolf & Werner Poewe. (2014) Perimenstrual Fluctuations in Two Siblings With Early-Onset Parkinson's Disease. Movement Disorders Clinical Practice 1:2, pages 125-127.
Crossref
Crossref
Richelin V. Dye, Karen J. Miller, Elyse J. Singer & Andrew J. Levine. (2012) Hormone Replacement Therapy and Risk for Neurodegenerative Diseases. International Journal of Alzheimer's Disease 2012, pages 1-18.
Crossref
Crossref
Katerina E. Paleologou & Omar M. A. El-Agnaf. 2012. Protein Aggregation and Fibrillogenesis in Cerebral and Systemic Amyloid Disease. Protein Aggregation and Fibrillogenesis in Cerebral and Systemic Amyloid Disease
109
164
.
Glenda E. Gillies & Simon McArthur. (2010) Estrogen Actions in the Brain and the Basis for Differential Action in Men and Women: A Case for Sex-Specific Medicines. Pharmacological Reviews 62:2, pages 155-198.
Crossref
Crossref
Glenda E. Gillies & Simon McArthur. (2010) Independent influences of sex steroids of systemic and central origin in a rat model of Parkinson's disease: A contribution to sex-specific neuroprotection by estrogens. Hormones and Behavior 57:1, pages 23-34.
Crossref
Crossref
Elisabetta Vegeto, Valeria Benedusi & Adriana Maggi. (2008) Estrogen anti-inflammatory activity in brain: A therapeutic opportunity for menopause and neurodegenerative diseases. Frontiers in Neuroendocrinology 29:4, pages 507-519.
Crossref
Crossref
M.C. Morale, F. L'Episcopo, C. Tirolo, G. Giaquinta, S. Caniglia, N. Testa, P. Arcieri, P.-A. Serra, G. Lupo, M. Alberghina, N. Harada, S. Honda, G.C. Panzica & Bianca Marchetti. (2008) Loss of aromatase cytochrome P450 function as a risk factor for Parkinson's disease?. Brain Research Reviews 57:2, pages 431-443.
Crossref
Crossref
Larissa Arning, Carsten Saft, Stefan Wieczorek, Jürgen Andrich, Peter H. Kraus & Jörg T. Epplen. (2007) NR2A and NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific manner. Human Genetics 122:2, pages 175-182.
Crossref
Crossref
Bin Liu & Dean E Dluzen. (2007) OESTROGEN AND NIGROSTRIATAL DOPAMINERGIC NEURODEGENERATION: ANIMAL MODELS AND CLINICAL REPORTS OF PARKINSON'S DISEASE. Clinical and Experimental Pharmacology and Physiology 34:7, pages 555-565.
Crossref
Crossref
Simon McArthur, Hilary E. Murray, Alihusein Dhankot, David T. Dexter & Glenda E. Gillies. (2007) Striatal susceptibility to a dopaminergic neurotoxin is independent of sex hormone effects on cell survival and DAT expression but is exacerbated by central aromatase inhibition. Journal of Neurochemistry 100:3, pages 678-692.
Crossref
Crossref
Farida Sohrabji & Danielle K. Lewis. (2006) Estrogen–BDNF interactions: Implications for neurodegenerative diseases. Frontiers in Neuroendocrinology 27:4, pages 404-414.
Crossref
Crossref
S. POZZI, V. BENEDUSI, A. MAGGI & E. VEGETO. (2006) Estrogen Action in Neuroprotection and Brain Inflammation. Annals of the New York Academy of Sciences 1089:1, pages 302-323.
Crossref
Crossref
M.C. Morale, P.A. Serra, F. L’Episcopo, C. Tirolo, S. Caniglia, N. Testa, F. Gennuso, G. Giaquinta, G. Rocchitta, M.S. Desole, E. Miele & B. Marchetti. (2006) Estrogen, neuroinflammation and neuroprotection in Parkinson’s disease: Glia dictates resistance versus vulnerability to neurodegeneration. Neuroscience 138:3, pages 869-878.
Crossref
Crossref
C. Isgor & S.J. Watson. (2005) Estrogen receptor α and β mRNA expressions by proliferating and differentiating cells in the adult rat dentate gyrus and subventricular zone. Neuroscience 134:3, pages 847-856.
Crossref
Crossref
L Westberg, A Håkansson, J Melke, H.Niazi Shahabi, S Nilsson, S Buervenich, A Carmine, J Ahlberg, M.B Grundell, B Schulhof, K Klingborg, B Holmberg, O Sydow, L Olson, E.B Johnels, E Eriksson & H Nissbrandt. (2004) Association between the estrogen receptor beta gene and age of onset of Parkinson’s disease. Psychoneuroendocrinology 29:8, pages 993-998.
Crossref
Crossref
Glenda E Gillies, Hilary E Murray, David Dexter & Simon McArthur. (2004) Sex dimorphisms in the neuroprotective effects of estrogen in an animal model of Parkinson's disease. Pharmacology Biochemistry and Behavior 78:3, pages 513-522.
Crossref
Crossref
A. AscherioH. ChenM.A. SchwarzschildS.M. ZhangG.A. ColditzF.E. Speizer. (2003) Caffeine, postmenopausal estrogen, and risk of Parkinson’s disease. Neurology 60:5, pages 790-795.
Crossref
Crossref
Krishna P. Datla, Hilary E. Murray, Arani V. Pillai, Glenda E. Gillies & David T. Dexter. (2003) Differences in dopaminergic neuroprotective effects of estrogen during estrous cycle. NeuroReport 14:1, pages 47-50.
Crossref
Crossref
H.E. Murray, A.V. Pillai, S.R. McArthur, N. Razvi, K.P. Datla, D.T. Dexter & G.E. Gillies. (2003) Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminergic pathway of adult rats: differential actions of estrogen in males and females. Neuroscience 116:1, pages 213-222.
Crossref
Crossref
K.L. Tsang, H. Jiang, D.B. Ramsden & S.L. Ho. (2001) The use of estrogen in the treatment of Parkinson's disease. Parkinsonism & Related Disorders 8:2, pages 133-137.
Crossref
Crossref
G.E. Hoffman, W.W. Le, A.Z. Murphy & C.L. Koski. (2001) Divergent Effects of Ovarian Steroids on Neuronal Survival during Experimental Allergic Encephalitis in Lewis Rats. Experimental Neurology 171:2, pages 272-284.
Crossref
Crossref
Maria D. Benedetti, Demetrius M. Maraganore, James H. Bower, Shannon K. McDonnell, Brett J. Peterson, J. Eric Ahlskog, Daniel J. Schaid & Walter A. Rocca. (2001) Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: An exploratory case‐control study. Movement Disorders 16:5, pages 830-837.
Crossref
Crossref
Susan J LeeBruce S McEwen. (2001) Neurotrophic and Neuroprotective Actions of Estrogens and Their Therapeutic Implications. Annual Review of Pharmacology and Toxicology 41:1, pages 569-591.
Crossref
Crossref
X Gao & D.E Dluzen. (2001) Tamoxifen abolishes estrogen's neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Neuroscience 103:2, pages 385-394.
Crossref
Crossref
K. KompolitiC.L. ComellaJ.A. JaglinS. LeurgansR. RamanC.G. Goetz. (2000) Menstrual-related changes in motoric function in women with Parkinson’s disease. Neurology 55:10, pages 1572-1575.
Crossref
Crossref
Hubert H. Fernandez & Kate L. Lapane. (2000) Estrogen use among nursing home residents with a diagnosis of Parkinson's disease. Movement Disorders 15:6, pages 1119-1124.
Crossref
Crossref
Pattie S. Green & James W. Simpkins. (2000) Neuroprotective effects of estrogens: potential mechanisms of action. International Journal of Developmental Neuroscience 18:4-5, pages 347-358.
Crossref
Crossref
Kin-Lun TsangShu-Leong HoSing-Kai Lo. (2000) Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology 54:12, pages 2292-2298.
Crossref
Crossref
P.J. BlanchetJ. FangK. HylandL.A. ArnoldM.M. MouradianT.N. Chase. (1999) Short-term effects of high-dose 17β-estradiol in postmenopausal PD patients. Neurology 53:1, pages 91-91.
Crossref
Crossref
Kenji Isoe‐Wada, Masanobu Maeda, Ji Yong, Yoshiki Adachi, Hideaki Harada, Katsuya Urakami & Kenji Nakashima. (2003) Positive association between an estrogen receptor gene polymorphism and Parkinson's disease with dementia. European Journal of Neurology 6:4, pages 431-435.
Crossref
Crossref
D.R. Session, M.M. Pearlstone, R. Jewelewicz & A.C. Kelly. (1994) Estrogens and Parkinson's disease. Medical Hypotheses 42:4, pages 280-282.
Crossref
Crossref
U. Bonuccelli, P. Piccini, A. Napolitano, A. Cagnacci, G. B. Melis, G. U. Corsini & A. Muratorio. 1991. The Basal Ganglia III. The Basal Ganglia III
733
741
.
Ubaldo Bonuccelli, Aldo Nocchiero, Alessandro Napolitano, Anna Maria Paoletti, Gian Benedetto Melis, Giovanni Umberto Corsini & Alberto Muratorio. (2004) Domperidone‐induced acute dystonia and polycystic ovary syndrome. Movement Disorders 6:1, pages 79-81.
Crossref
Crossref